Pharmaceutical

EC authorises Sydnexis’ paediatric myopia treatment

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Jun 7, 2025 - 06:00
EC authorises Sydnexis’ paediatric myopia treatment
The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.
Read the original article

Tags:

Previous Article

Juvenescence enhances AI drug discovery with Ro5 acquisition

Next Article

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Hospitals offer their custom-built tech for sale in search of new revenue streams

STAT+: Hospitals offer their custom-built tech for sale...

Jan 20, 2024

Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

Health Canada approves Servier’s VORANIGO for IDH-mutan...

Oct 24, 2024

WHO member states agree on treaty to fight future pandemics

WHO member states agree on treaty to fight future pande...

Apr 18, 2025